logo

Aveo Pharmaceuticals, Inc. (AVEO)



Trade AVEO now with
  Date
  Headline
5/8/2018 7:12:36 AM AVEO Oncology Q1 Net Loss $9.0 Mln Or $0.08/shr Vs. Net Loss $8.8 Mln Or $0.12/shr Last Year
3/13/2018 7:16:21 AM AVEO Oncology FY Net Loss $65.0 Mln Or $0.61/Shr Vs Loss Of $26.9 Mln Or $0.39/Shr Last Year
3/13/2018 7:15:33 AM AVEO Oncology 2017 Total Collaboration Revenue $7.6 Mln Vs $2.5 Mln Last Year
2/12/2018 7:07:10 AM AVEO Announces EUSA Pharma Granted Positive NICE Recommendation For FOTIVDA As First Line Treatment For ARCC
2/10/2018 11:09:35 AM AVEO Oncology, EUSA Pharma Say Encouraging Preliminary From Phase 2 Results Of TiNivo Study In Renal Cell Carcinoma
11/13/2017 10:07:53 AM B. Riley FBR Initiates AVEO Pharmaceuticals, Inc. (AVEO) At Buy With $5 Price Target
3/30/2016 8:30:46 AM FBR Capital Markets Initiates AVEO Pharmaceuticals, Inc. (AVEO) At Outperform With $3 Price Target
5/8/2014 1:36:55 PM RBC Capital Markets Is Increasing AVEO Pharmaceuticals, Inc. (AVEO) FY 14 Rev. Estimate To 16.0 M From 1.0 M
5/8/2014 1:36:09 PM RBC Capital Markets Is Cutting AVEO Pharmaceuticals, Inc. (AVEO) 3Q14 Estimate To -0.24 From -0.21
5/8/2014 1:35:47 PM RBC Capital Markets Is Lowering AVEO Pharmaceuticals, Inc. (AVEO) 2Q14 Estimate To -0.29 From -0.26
5/8/2014 1:34:57 PM RBC Capital Markets Is Increasing AVEO Pharmaceuticals, Inc. (AVEO) 1Q14 Estimate To -0.12 From -0.28
5/8/2014 1:34:36 PM RBC Capital Markets Is Increasing AVEO Pharmaceuticals, Inc. (AVEO) FY14 Estimate To -0.85 From -0.95
3/14/2014 8:42:51 AM RBC Capital Markets Is Raising AVEO Pharmaceuticals, Inc. (AVEO) FY14 Estimate To -0.95 From -1.09
12/16/2013 9:13:03 AM RBC Capital Markets Is Increasing AVEO Pharmaceuticals, Inc. (AVEO) FY14 Estimate To -1.09 From -1.10
12/16/2013 9:10:52 AM RBC Capital Markets Is Cutting AVEO Pharmaceuticals, Inc. (AVEO) FY13 Estimate To -2.06 From -1.90
12/16/2013 9:05:25 AM RBC Capital Markets Cuts AVEO Pharmaceuticals, Inc. (AVEO) To Underperform From Sector Perform With $2 down from $5 Price Target
5/3/2013 9:00:31 AM RBC Capital Markets Downgrades AVEO Pharmaceuticals, Inc. (AVEO) To Sector Perform From Outperform With $6 down from $15 Price Target
4/26/2013 10:06:02 AM RBC Capital Markets Is Cutting AVEO Pharmaceuticals, Inc. (AVEO) Q4 13 Rev. Estimate To 7.6 M From 7.8 M
  
 
>